Related Experiment Video
Updated: Mar 24, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR
Xiao-Dong Yu1, Rui Yang2, Chang-Jun Leng3
1Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou 318000, China.
Abstract:
Human epidermal growth factor receptor (EGFR) plays a central role in the pathological progression and metastasis of lung cancer; the development and clinical application of therapeutic agents that target the receptor provide important insights for new lung cancer therapies. The tumor-suppressor protein MIG6 is a negative regulator of EGFR, which can bind at the activation interface of asymmetric dimer of EGFR kinase domains to disrupt dimerization and then inactivate the kinase (Zhang X. et al. Nature 2007, 450: 741-744). The protein adopts two separated segments, i.e. MIG6(segment 1) and MIG6(segment 2), to directly interact with EGFR. Here, computational modeling and analysis of the intermolecular interaction between EGFR kinase domain and MIG6(segment 2) peptide revealed that the peptide is folded into a two-stranded β-sheet composed of β-strand 1 and β-strand 2; only the β-strand 2 can directly interact with EGFR activation loop, while leaving β-strand 1 apart from the kinase. A C-terminal island within the β-strand 2 is primarily responsible for peptide binding, which was truncated from the MIG6(segment 2) and exhibited weak affinity to EGFR kinase domain. Structural and energetic analysis suggested that phosphorylation at residues Tyr394 and Tyr395 of truncated peptide can considerably improve EGFR affinity, and mutation of other residues can further optimize the peptide binding capability. Subsequently, three derivative versions of the truncated peptide, including phosphorylated and dephosphorylated peptides as well as a double-point mutant were synthesized and purified, and their affinities to the recombinant protein of human EGFR kinase domain were determined by fluorescence anisotropy titration. As expected theoretically, the dephosphorylated peptide has no observable binding to the kinase, and phosphorylation and mutation can confer low and moderate affinities to the peptide, respectively, suggesting a good consistence between the computational analysis and experimental assay.
Insights
The tumor suppressor MIG6 regulates epidermal growth factor receptor (EGFR) in lung cancer. Computational and experimental studies show that modifying a key MIG6 peptide segment enhances its binding affinity to EGFR, offering new therapeutic strategies.
Area of Science:
- Molecular biology
- Biochemistry
- Structural biology
Background:
- Epidermal growth factor receptor (EGFR) is crucial in lung cancer progression and metastasis.
- Tumor suppressor MIG6 negatively regulates EGFR activity by disrupting its dimerization.
- MIG6 utilizes two distinct segments to interact with the EGFR kinase domain.
Purpose of the Study:
- To computationally model and analyze the interaction between the EGFR kinase domain and MIG6 segment 2 peptide.
- To investigate the binding affinity of modified MIG6 peptides to the EGFR kinase domain.
- To explore potential therapeutic strategies targeting EGFR in lung cancer.
Main Methods:
- Computational modeling and analysis of intermolecular interactions.
- Truncation of MIG6 segment 2 to create a peptide fragment.
- Synthesis and purification of peptide derivatives (phosphorylated, dephosphorylated, double-point mutant).
- Fluorescence anisotropy titration to determine binding affinities to recombinant human EGFR kinase domain.
Main Results:
- MIG6 segment 2 peptide adopts a two-stranded β-sheet structure, with β-strand 2 interacting with the EGFR activation loop.
- A C-terminal region within β-strand 2 is critical for peptide binding.
- Phosphorylation and specific mutations significantly enhance the binding affinity of the truncated MIG6 peptide to EGFR kinase domain.
- Experimental results align with computational predictions, showing improved binding with phosphorylation and mutation.
Conclusions:
- The study elucidates the structural basis of MIG6-EGFR interaction at the peptide level.
- Phosphorylation and mutation of MIG6-derived peptides can modulate their affinity for EGFR.
- These findings provide a foundation for developing novel EGFR-targeted therapies for lung cancer.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...

